Cullen Investment Group LTD. Cuts Position in IQVIA Holdings Inc. $IQV

Cullen Investment Group LTD. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,941 shares of the medical research company’s stock after selling 3,199 shares during the quarter. Cullen Investment Group LTD.’s holdings in IQVIA were worth $5,076,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Claret Asset Management Corp raised its holdings in IQVIA by 1.1% in the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after buying an additional 53 shares in the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the last quarter. CVA Family Office LLC raised its stake in shares of IQVIA by 11.6% during the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after acquiring an additional 68 shares in the last quarter. Finally, Huntington National Bank lifted its position in IQVIA by 7.8% during the third quarter. Huntington National Bank now owns 969 shares of the medical research company’s stock valued at $184,000 after acquiring an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.3%

NYSE IQV opened at $165.54 on Thursday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a fifty day simple moving average of $189.63 and a two-hundred day simple moving average of $205.63. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $28.09 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.60 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IQV. Jefferies Financial Group lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a report on Thursday, February 5th. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Royal Bank Of Canada assumed coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Finally, Morgan Stanley set a $240.00 price target on IQVIA in a research note on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $229.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.